Michael Catelani - 01 Jun 2021 Form 4 Insider Report for Anixa Biosciences Inc (ANIX)

Role
COO & CFO
Signature
/s/ Michael J. Catelani
Issuer symbol
ANIX
Transactions as of
01 Jun 2021
Transactions value $
$0
Form type
4
Filing time
02 Jun 2021, 17:00:21 UTC
Next filing
02 Nov 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANIX Employee Stock Option (Right to Buy) Award $0 +100,000 $0 100,000 01 Jun 2021 Common Stock 100,000 $4.02 Direct F1, F2
transaction ANIX Employee Stock Option (Right to Buy) Award $0 +100,000 $0 100,000 01 Jun 2021 Common Stock 100,000 $4.02 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan.
F2 The options vest and become exercisable as follows: (i) 25,000 shares vest if during any 5 trading day period, the average closing price of the issuer's common stock is at least $5.00, (ii) 25,000 shares vest if during any 5 trading day period, the average closing price of the issuer's common stock is at least $6.00, (iii) 25,000 shares vest if during any 5 trading day period, the average closing price of the issuer's common stock is at least $7.00, and (iv) 25,000 shares vest if during any 5 trading day period, the average closing price of the issuer's common stock is at least $8.00.
F3 The options vest and become exercisable in thirty-six (36) equal monthly installments beginning June 30, 2021.